Psychedelic Science Newsletter
Issue #22January 27, 20267 studies

Trip dialogue predicted sobriety — and ketamine works via adenosine, not just NMDA receptors

New research is revealing unexpected mechanisms behind psychedelic therapy—from how people talk about their trips to the surprising metabolic pathways that make ketamine work.

🗣️ What People Say After Psychedelic Trips Predicts Alcohol Sobriety

  • 20 people with alcohol use disorder and depression received 25mg psilocybin, then had integration sessions the day after—55% stayed sober for 3 months

  • Those who stayed sober talked about inner dialogue, family connections, and new coping strategies for alcohol triggers, while those who relapsed focused on physical sensations, negative emotions, and suppressive coping

  • The content was analyzed using software that classified 88% of 127,760 spoken words into two distinct patterns—active cognitive processing versus sensory/emotional descriptions

Why it matters: The way people process and talk about their psychedelic experience may be more predictive of long-term outcomes than the trip itself, suggesting integration sessions could be optimized to focus on cognitive restructuring rather than just emotional support.

🥉 Top 5% journal 🔗 Journal of affective disorders Journal Article 🗓️ Jan 20

Key Findings

🔋 Ketamine's Antidepressant Effects May Work Through Energy Metabolism, Not Just Brain Receptors

  • New research suggests ketamine, ECT, and acute intermittent hypoxia all trigger rapid antidepressant effects through adenosine signaling—the same molecule involved in cellular energy and sleep regulation

  • The mechanism primarily involves modulation of mitochondrial metabolism rather than NMDA receptor antagonism, which has been the leading theory for ketamine's effects

  • This metabolic pathway could explain why chronic caffeine use (which blocks adenosine) might interfere with treatment response in depression

💡 This adenosine pathway could lead to ketamine derivatives with better therapeutic profiles and fewer side effects.

💊 Racemic Ketamine Performs Nearly as Well as Expensive Esketamine

  • 76 patients with treatment-resistant depression received either FDA-approved intranasal esketamine or off-label racemic ketamine over 4 weeks

  • Both groups showed similar symptom improvement (-9.3 vs -10.0 points on depression scales), meeting non-inferiority criteria

  • Esketamine had higher remission rates (38.7% vs 15.6%), but racemic ketamine could offer a more accessible and affordable alternative where esketamine access is limited

💡 Generic racemic ketamine may provide similar benefits to the expensive branded esketamine, potentially expanding access to ketamine therapy.
🥉 Top 5% journal 🔗 Journal of affective disorders Journal Article 🗓️ Jan 23

🧬 DNA Methylation Patterns Predict Ketamine Response in PTSD

  • Machine learning analysis of pre-treatment blood samples from PTSD patients identified 1,208 methylation sites that predicted ketamine treatment response with 92.9% accuracy

  • The predictive DNA methylation sites were enriched near genes involved in glutamatergic signaling and immune regulation, as well as established PTSD risk loci

  • This came from the largest randomized ketamine-PTSD study, which found no overall benefit of ketamine over placebo, highlighting the need to identify responsive subgroups

💡 Blood tests measuring DNA methylation patterns could identify which PTSD patients are most likely to benefit from ketamine before treatment begins.
🎖️ Top 10% journal 🔗 iScience Journal Article 🗓️ Jan 21

⚡ More Preparation Therapy Sessions Boost Psychedelic Treatment Outcomes

  • Meta-analysis of 12 controlled trials with 733 participants found that more hours of preparation therapy before psychedelic dosing was significantly associated with greater symptom reduction

  • Psychedelic-assisted therapy showed large overall effects (Hedges g = -0.84) compared to control conditions across all studies

  • Hours of post-dosing integration therapy and total session count showed no significant association with outcomes, suggesting preparation may be the critical therapeutic component

💡 The therapy that happens before the psychedelic experience may be more important than the integration work that follows.
🥈 Top 2% journal 🔗 JAMA network open Systematic Review 🗓️ Jan 21

📈 ECT Works Faster Than Ketamine for Severe Depression

  • Meta-analysis of 7 studies with 731 participants found ECT led to faster improvement than ketamine, with approximately 0.02 standardized mean difference per day

  • By the end of 4 weeks, ECT showed a projected moderate efficacy advantage (SMD = 0.59) over ketamine for major depressive disorder

  • Patients receiving ketamine had significantly lower depression scores at baseline compared to ECT patients, suggesting different severity populations

💡 For patients needing rapid relief from severe depression, ECT may still be the faster-acting option despite ketamine's growing popularity.
🥉 Top 5% journal 🔗 Translational psychiatry Systematic Review 🗓️ Jan 23

🎯 Mindset Matters More Than Molecule Type for Mystical Experiences

  • 397 adults reported on their most intense experiences with psilocybin, MDMA, or cannabis—psilocybin and MDMA produced greater mystical experiences than cannabis, but effect sizes were small (β = 0.14-0.34)

  • When psychological factors were included, mindset variables like surrendering to the experience and spiritual motivations accounted for up to 58% of variance in mystical experiences

  • Substance type alone accounted for only 10% of variance, with 83% reporting recreational use and 75% using other substances concurrently

💡 Set and setting may be more important than which psychedelic substance someone takes for achieving meaningful experiences.
Top 20% journal 🔗 BMC psychology Journal Article 🗓️ Jan 22

Implications

These findings suggest psychedelic therapy is more complex than just giving someone a drug—the preparation work, integration dialogue, and even metabolic pathways like adenosine signaling may be as important as the psychedelic compounds themselves. Meanwhile, accessibility issues with expensive treatments like esketamine are driving research into more affordable alternatives that may work nearly as well.

Studies in this issue

Primary sources used for this newsletter.

  1. How reflections after a psychedelic session relate to 3-month drinking abstinence in people with alcohol use disorder and depression
    main storyJournal of affective disorders2026-01-20PMID 41558304
  2. Comparing nasal racemic ketamine and esketamine for hard-to-treat depression in real-world patients
    key findingJournal of affective disorders2026-01-23PMID 41577046
  3. Adenosine's role in fast antidepressant effects: Understanding the coffee paradox
    key findingBrain medicine : from neurons to behavior and better health2026-01-23PMID 41573274
  4. Comparing self-transcendent and mystical feelings during psilocybin, MDMA, and cannabis use
    key findingBMC psychology2026-01-22PMID 41566347
  5. DNA markers and clinical traits together may predict ketamine response in PTSD
    key findingiScience2026-01-21PMID 41561376
  6. Amount of Talk Therapy and Reduction of Depression Symptoms in Psychedelic-Assisted Treatment
    key findingJAMA network open2026-01-21PMID 41563753
  7. Timing matters: Comparing ECT and ketamine for depression through a review and analysis
    key findingTranslational psychiatry2026-01-23PMID 41577654

Continue reading

All Psychedelic Science issues